Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Archexin plus gemcitabine in metastatic pancreatic cancer
NCT01028495Phase 2Completed
- Sponsor
- Rexahn Pharmaceuticals
- Start
- May 2009
- Primary completion
- Jul 2012
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
A Phase 2 trial of Archexin, sponsored by Rexahn Pharmaceuticals. Started May 2009; status: completed.
02
Drugs
Archexin
Beyond the preview
Go deeper on NCT01028495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01028495.